The Oral Peptide Revolution: How Drug Designers Are Breaking the Bioavailability Barrier

The FDA approved ICOTYDE (icotrokinra) on 18 March 2026 for moderate-to-severe plaque psoriasis in adults and in patients aged 12 and over weighing at least 40 kg.¹ It is a 13-amino-acid cyclic peptide, taken as a tablet once a day, that blocks the interleukin-23 receptor, and in Phase 3 trials it outperformed both placebo and an oral small molecule.²³ The interesting part for peptide science is not the dermatology. It is that the molecule achieves this with an oral bioavailability of a few tenths of one percent and no absorption enhancer at all. Condor Research supplies reference materials for laboratory research use only; this article is commentary on drug design and contains no human use guidance.

What was approved, and by whom?

Icotrokinra, marketed as ICOTYDE, was approved by the FDA on 18 March 2026, held by Johnson and Johnson through Janssen Biotech, and originating from a discovery collaboration with Protagonist Therapeutics, where the molecule carried the designations JNJ-77242113 and PN-235.¹ The approved indication covers moderate-to-severe plaque psoriasis in adults and in paediatric patients aged 12 years and older weighing at least 40 kg. In Europe the CHMP adopted a positive opinion on 23 July 2026, with a European Commission decision still outstanding when this page was written.⁶

It is described by its sponsor as a targeted oral peptide, and it is the first approved oral peptide antagonist of the interleukin-23 receptor. That phrasing is worth keeping precise: oral peptide medicines already existed, and what is new is the target class and the route together.

What did the trials actually show?

ICONIC-LEAD randomised 684 adults and adolescents 2:1 to icotrokinra 200 mg once daily or placebo.² At week 16, 65% of the icotrokinra group reached an Investigator’s Global Assessment score of 0 or 1 against 8% on placebo, and 50% reached PASI 90 against 4%. Complete clearance was reported in 33% versus 1% by IGA and 27% versus under 1% by PASI 100. Adverse events through week 16 occurred in 49% of participants in each group.

ICONIC-ADVANCE 1 and 2 added an active comparator, the oral small molecule deucravacitinib, across 149 and 114 sites.³ IGA 0 or 1 at week 16 was reached by 68% on icotrokinra against 11% on placebo in the first trial and 70% against 9% in the second, and the peptide was superior to deucravacitinib on the co-primary endpoints, with adverse event rates similar to placebo. An oral peptide beating an oral small molecule at its own game is the result that makes this more than a formulation curiosity.

How does a peptide survive the gut at all?

Not by being protected, in this case, but by being built differently. Icotrokinra is a cyclic peptide of 13 amino acids, including non-canonical residues, closed through a disulfide bridge, with a molecular weight around 1.5 kilodaltons.⁴ Cyclisation and conformational restriction are the core tools here: a constrained ring is a poor substrate for proteases that evolved to process extended chains, and the same rigidity reduces the entropic cost of crossing a membrane. Non-natural residues remove the recognition motifs that gut enzymes depend on. The result is a molecule that is chemically a peptide and pharmacologically closer to an engineered small molecule. We set out the underlying barriers in why most peptides cannot be swallowed.

The molecule was not shielded from the gut. It was redesigned until the gut stopped recognising it as food.

Why is a bioavailability of 0.1 to 0.3% not a failure?

Because bioavailability is a ratio, not a dose. Published translational pharmacokinetics put icotrokinra’s oral bioavailability in animals at roughly 0.1% to 0.3%, achieved without any permeation enhancer, with the clinical dose taken fasting and a median time to peak concentration of about two hours.⁴ For comparison, oral semaglutide reaches something under 1% using SNAC as an absorption enhancer, and oral octreotide relies on a transient permeation enhancer that opens intestinal tight junctions.⁵

0.1-0.3% oral bioavailability in animal studies, with no absorption enhancer, in a drug that cleared three Phase 3 trials.

What matters clinically is whether the absorbed fraction, multiplied by the administered dose, exceeds the concentration needed at the target. A very potent molecule that is cheap to synthesise can afford to waste 99.8% of each tablet. That trade is only available to a chemically synthesised peptide: it would be economically impossible for a biologic expressed in cell culture, which is one reason the antibody route never produced an oral version of this mechanism. The engineering objective was never to maximise the percentage. It was to make the absorbed amount reliable enough to dose.

How does this compare with other oral peptides?

Six approved oral peptide or cyclic-peptide medicines reaching their targets by six different routes. The absence of a shared method is the point: there is no general solution to oral peptide delivery, only individual ones.

What is coming behind it?

Protagonist has applied the same approach to other targets. PN-881, an oral peptide antagonist of interleukin-17, was in Phase 1 with Phase 2 planned, according to the company’s first-quarter 2026 update; we were unable to confirm a more recent status.⁷ A triple agonist programme at GLP-1, GIP and glucagon receptors, PN-477, exists in both a weekly subcutaneous and a once-daily oral formulation, with the oral version described at an investor conference on 9 September 2026 as running roughly four months behind the injectable, and no public trial registration identified.⁷ Treat both as company-reported pipeline status rather than verified clinical fact.

The pattern is the part worth watching. If an oral peptide can antagonise a cytokine receptor, the question becomes which injectable mechanisms are candidates for the same treatment, and the incretin field is the obvious commercial answer. We looked at what it costs to compare the two routes for a single molecule in our piece on the same peptide injected and swallowed.

What has not changed

Most peptides still cannot be swallowed, and nothing about this approval alters that. Each oral peptide approved so far is a bespoke solution to its own molecule’s problems, and the table above shows six drugs solving the same barrier six different ways. There is no platform that converts an injectable peptide into an oral one; there is a growing toolkit, applied case by case, at the cost of a full medicinal chemistry programme each time. A sequence that works as an injection is not a candidate for oral delivery simply because it is a peptide, and claims that a given research compound is orally active require evidence for that compound, by that route, at that dose.

What is established, and what is not

Established: icotrokinra is approved in the United States, it is an orally administered cyclic peptide blocking the IL-23 receptor, and in three Phase 3 trials it was superior to placebo and, in two of them, to an oral comparator, with adverse event rates similar to placebo through week 16.

Not established: long-term safety and durability, which the ICONIC-LEAD authors themselves flag as requiring longer follow-up; European authorisation, which was pending at the time of writing; and the status of the follow-on oral programmes beyond company statements. Unresolved for the field: whether the design principles that worked here generalise to larger peptides or to targets requiring higher systemic exposure. What would change the assessment: a second independent oral peptide approval at a different target class, which would turn a demonstration into a method.

How this was checked. The ICONIC-LEAD and ICONIC-ADVANCE results were read from the published abstracts in the New England Journal of Medicine and The Lancet on 13 September 2026, and every trial figure quoted here comes from those papers rather than from press coverage. Molecular and pharmacokinetic properties come from the published translational pharmacokinetics paper. The approval date and indication come from the sponsor’s announcement and FDA materials. Pipeline status for PN-881 and PN-477 is attributed to company communications and flagged as unverified. Version 1.0, first published 13 September 2026.

Condor Research supplies characterised reference materials for laboratory research use only: not for human or veterinary use, not for diagnostic or therapeutic application, and not for any food or cosmetic purpose. We do not supply any medicine discussed here. Doses cited are trial parameters reported as scientific findings, not guidance for any person, and this article is not medical advice.

Condor Research · Scientific desk
Atrio Sciences s.r.o., IČO 57 669 651, Nitra (SK) · info@condorresearch.com